The action profiles of human NPH insulin preparations
- PMID: 2523785
- DOI: 10.1111/j.1464-5491.1989.tb01154.x
The action profiles of human NPH insulin preparations
Abstract
The complete time-action profiles of four subcutaneously injected human NPH insulin preparations (Protaphane HM/Novo; Insulatard Human/Nordisk; Huminsulin Basal/Eli Lilly; Basal H-Insulin/Hoechst) have been investigated by means of the euglycaemic clamp technique (blood glucose 5.0 mmol l-1). Six normal male subjects were connected to a Biostator on five occasions in randomized order including a control study without insulin injection. A stable basal insulin level of about 10 mU l-1 was established by means of a low dose insulin infusion (0.1 mU kg-1 min-1) which subsequently suppressed C-peptide by 35 +/- 19% (mean +/- SD) to levels of around 0.3 nmol l-1. Twelve units of NPH insulin were injected subcutaneously into the abdominal wall and glucose infusion rates were monitored for 19 h. In the control study, the mean glucose infusion rate was 1.11 +/- 0.60 (range 0.32-1.95) mg kg-1 min-1. Maximal glucose infusion rates, reached 5-7 h after injection, were comparable (4.3-4.9 mg kg-1 min-1) for the four different preparations used. Glucose infusion rates returned to basal rates within the 19 h study period. Mean plasma free insulin levels peaked at 17.5-18.6 mU l-1 3-4.5 h after injection and returned to basal levels within 16 h. The time ranges of greater than 90, greater than 75, greater than 50, and greater than 25% of maximal insulin action (as estimated from glucose infusion rates) revealed no significant differences between the four insulin preparations tested. No significant insulin action was observed beyond 17 h after insulin injection of any preparation.
Similar articles
-
Insulin concentrations and time-action profiles of three different intermediate-acting insulin preparations in nondiabetic volunteers under glucose-controlled glucose infusion technique.Diabetes Care. 1982 Nov-Dec;5 Suppl 2:43-52. doi: 10.2337/diacare.5.2.s43. Diabetes Care. 1982. PMID: 6765540
-
Similarity of pharmacodynamic effects of a single injection of insulin glargine, insulin detemir and NPH insulin on glucose metabolism assessed by 24-h euglycaemic clamp studies in healthy humans.Diabet Med. 2010 Jul;27(7):830-7. doi: 10.1111/j.1464-5491.2010.03026.x. Diabet Med. 2010. PMID: 20636965 Clinical Trial.
-
The effect of glimepiride on pancreatic beta-cell function under hyperglycaemic clamp and hyperinsulinaemic, euglycaemic clamp conditions in non-insulin-dependent diabetes mellitus.Horm Metab Res. 1996 Sep;28(9):445-50. doi: 10.1055/s-2007-979835. Horm Metab Res. 1996. PMID: 8911981 Clinical Trial.
-
Kinetics and metabolic activity of biosynthetic NPH insulin evaluated by the glucose clamp technique.Diabetes Care. 1984 Mar-Apr;7(2):132-6. doi: 10.2337/diacare.7.2.132. Diabetes Care. 1984. PMID: 6376009
-
Pharmacokinetics and pharmacodynamics of subcutaneously administered U40 and U100 formulations of regular human insulin.Diabete Metab. 1992 Jan-Feb;18(1):21-4. Diabete Metab. 1992. PMID: 1563532
Cited by
-
Comparative dose-related time-action profiles of glibenclamide and a new non-sulphonylurea drug, AG-EE 623 ZW, during euglycaemic clamp in healthy subjects.Diabetologia. 1994 Jul;37(7):703-7. doi: 10.1007/BF00417695. Diabetologia. 1994. PMID: 7958542 Clinical Trial.
-
Reduction in C-Peptide Levels and Influence on Pharmacokinetics and Pharmacodynamics of Insulin Preparations: How to Conduct a High-Quality Euglycemic Clamp Study.Front Pharmacol. 2021 Dec 2;12:786613. doi: 10.3389/fphar.2021.786613. eCollection 2021. Front Pharmacol. 2021. PMID: 34925042 Free PMC article.
-
How to Achieve Sufficient Endogenous Insulin Suppression in Euglycemic Clamps Assessing the Pharmacokinetics and Pharmacodynamics of Long-Acting Insulin Preparations Employing Healthy Volunteers.Front Pharmacol. 2022 Jul 22;13:899798. doi: 10.3389/fphar.2022.899798. eCollection 2022. Front Pharmacol. 2022. PMID: 35935883 Free PMC article.
-
Fitting nonlinear regression models with correlated errors to individual pharmacodynamic data using SAS software.J Pharmacokinet Biopharm. 1995 Feb;23(1):87-100. doi: 10.1007/BF02353787. J Pharmacokinet Biopharm. 1995. PMID: 8576846
-
Long-term efficacy and safety of insulin detemir compared to Neutral Protamine Hagedorn insulin in patients with Type 1 diabetes using a treat-to-target basal-bolus regimen with insulin aspart at meals: a 2-year, randomized, controlled trial.Diabet Med. 2008 Apr;25(4):442-9. doi: 10.1111/j.1464-5491.2007.02407.x. Diabet Med. 2008. PMID: 18387078 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Research Materials
Miscellaneous